Immune Thrombocytopenia in Children: Consensus and Controversies
- 11 January 2020
- journal article
- review article
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 87 (2) , 150-157
Abstract
Newly diagnosed immune thrombocytopenia (ITP) is a relatively common disorder of childhood that does not require an exhaustive laboratory workup for diagnosis. A history and physical exam with a review of the peripheral smear are crucial for excluding secondary causes of thrombocytopenia. Several guidelines have been published to guide physicians in the management of ITP. However, the decision for treatment can be arduous. The management strategy should not be focussed on the platelet count but the severity of bleeding symptoms. Agents for treating acute ITP, including corticosteroids, immunoglobulin and anti-D immunoglobulin, do not seem to have a significant impact on the natural history of the disease. The majority of children with ITP do not need therapy and have a spontaneous resolution of the disease. Some children can develop chronic ITP that is not commonly life-threatening but can lead to impaired quality of life. Traditional therapies such as rituximab and splenectomy for chronic ITP are not without significant adverse effects. Thrombopoietin receptor agonists are newer agents for the treatment of chronic ITP and hold promise, however, their cost currently precludes use in most of the patients in low-middle-income countries. This review compares and contrasts the specific treatments available for the treatment of ITP to help the reader make a balanced choice. This review, based on a series of case examples, will help physicians in making decisions about choosing a practical management strategy for patients with newly diagnosed as well as chronic ITP.Keywords
This publication has 48 references indexed in Scilit:
- Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopeniaBlood, 2012
- Rituximab for Children with Immune Thrombocytopenia: A Systematic ReviewPLOS ONE, 2012
- RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME)Transfusion, 2011
- Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 casesBlood, 2009
- Outcome of chronic idiopathic thrombocytopenic purpura in childrenPediatric Blood & Cancer, 2009
- Vascular complications after splenectomy for hematologic disordersBlood, 2009
- Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpuraBlood, 2008
- Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity?Archives of Disease in Childhood, 2007
- Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancyBritish Journal of Haematology, 2003
- Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelinesThe Lancet, 1997